Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
MiniMed Group, Inc. Common Stock(MMED)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for MMED
11/13/2026: MMED (4-star) is currently NOT-A-BUY. Pass it for now.
MiniMed Group, Inc. is a newly independent medical technology company that provides a comprehensive suite of automated diabetes management solutions. With a 40-year history as a leader in insulin pump therapy, the company is now focusing on a full-stack, automated insulin delivery ecosystem to capture growth in both Type 1 and Type 2 diabetes markets. While the company benefits from a massive clinical dataset and an established brand, it faces high execution risks, intense competition from agile peers, and ongoing separation-related costs. MiniMed may suit growth-oriented investors interested in the medtech space, though they should monitor product innovation and margin recovery closely.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | The company is a pure-play diabetes tech stock focused on scaling automated delivery systems in a high-growth sector. |
| Momentum investor | Strong fit while signal remains positive | High trading volume and strong analyst interest following the IPO provide significant momentum potential. |
| Value investor | Weak fit | The company currently shows net losses and is in an early-stage growth phase, making traditional value metrics less applicable. |
| Dividend investor | Weak fit | The company does not pay dividends and prioritizes reinvesting all available capital into growth. |
| Low-risk investor | Weak fit | High price volatility and the risks associated with a newly independent medical device company make this a high-risk equity. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | As a recently spun-out growth company, the stock is subject to significant price swings based on sentiment and analyst sentiment. |
| Valuation risk | Medium / high | The stock trades based on future growth expectations, leaving it vulnerable to de-ratings if growth targets are missed. |
| Competition risk (Diabetes Tech) | High | Continuous innovation from nimble competitors like Tandem and Insulet threatens to erode market share in the pump segment. |
| Business quality | Medium | While the technology is well-regarded, the company is still building the operational independence and scale required for a durable franchise. |
| Dividend income | Low / none | Investors should not expect income, as the company is focused entirely on capital reinvestment. |
| Execution risk | Medium / high | Successful management of the post-separation transition and the launch of new AID features is critical to long-term performance. |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 5.03B USD | Price to earnings Ratio - | 1Y Target Price 25.33 |
Price to earnings Ratio - | 1Y Target Price 25.33 | ||
Volume (30-day avg) 14.3M shares | Beta - | 52 Weeks Range 10.65 - 24.43 | Updated Date 11/13/2026 |
52 Weeks Range 10.65 - 24.43 | Updated Date 11/13/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.53 |
Sector & Industry Intelligence
Sector
Healthcare
Bullish- Sentiment
- Strong Bullish
- Momentum
- Momentum Steady
- BUY participation
- 62.6%
- Active BUY / eligible
- 72 / 115
- 30-Day BUY Count Change
- +35
- Market state
- Strong Bullish
The number of qualifying BUY stocks has remained relatively stable.
Industry
Medical Instruments & Supplies
- BUY participation
- 60.0%
- Active BUY / eligible
- 3 / 5
- 30-Day BUY Count Change
- +1
Eligible universe: 5 stocks.
Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.
Price Behavior
Rolling Over
The price momentum is slowing down and beginning to turn downward.
Choppy
The stock has experienced frequent reversals and pronounced short-term price swings.
Analysis of Past Performance
Type Stock | Historic Profit 32.14% | Avg. Invested days 75 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  5.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 11/13/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Insulin Pumps | Durable medical device hardware including the MiniMed system portfolio. | Hardware sales represent the primary entry point for patients into the MiniMed diabetes ecosystem. |
| Consumables & Sensors | Continuous glucose monitoring sensors, infusion sets, and reservoir replacements. | This segment provides a steady stream of recurring revenue as users require constant supplies for their pumps. |
| Digital Health & Software | CareLink platform and algorithmic delivery subscription services. | Software integrations increase customer stickiness and create higher-margin recurring revenue streams. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Valuation
Trailing PE - | Forward PE - | Enterprise Value 4.94B | Price to Sales(TTM) 1.56 |
Enterprise Value 4.94B | Price to Sales(TTM) 1.56 | ||
Enterprise Value to Revenue 1.53 | Enterprise Value to EBITDA 92.94 | Shares Outstanding 281.35M | Shares Floating 281.27M |
Shares Outstanding 281.35M | Shares Floating 281.27M | ||
Percent Insiders 0.12 | Percent Institutions 24.84 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.